$69 postpage LB

Mesoblast Submits Clinical Efficacy Safety Data to FDA

  • January 02, 2020 01:11 PM AEDT
  • Utkarsha Kalra
    Manager, PR and Media Relations Utkarsha Kalra
    5 Posts

    Utkarsha comes with an experience of over 7 years in financial and management reporting in one of the big four consultancy firms. Her expertise lies in developing communication strategies for business development, stakeholder management, conflict man...

Mesoblast Limited (ASX: MSB), a global leader in cellular medicine for inflammatory diseases, has announced that US FDA has approved company’s filing of clinical efficacy and safety data for remestemcel-L in its rolling Biologics License Application (BLA). Remestemcel-L will be used for the treatment of children with steroid-refractory acute graft versus host disease.

Gold MTF non-AMP

· Remestemcel-L is an investigational therapy comprising culture expanded mesenchymal stem cells derived from the bone marrow of unrelated donor;

· It is planned to be launched in the US in 2020, if approved.

At AEDT 12:51PM, MSB’s stock was trading at $2.080 per share, no change from its previous close.

· Remestemcel-L is an investigational therapy comprising culture expanded mesenchymal stem cells derived from the bone marrow of unrelated donor;

· It is planned to be launched in the US in 2020, if approved.

At AEDT 12:51PM, MSB’s stock was trading at $2.080 per share, no change from its previous close.

-->

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK